| FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $513.7M | ||||
| Company | Location | Date | Amt. (M) | Details |
| Affibody Holding AB |
Stockholm, Sweden | 4/4** | SEK200 ($28.5) | Affibody raised $28.5M through a private financing |
| Affimed Therapeutics AG |
Heidelberg, Germany | 4/4 | $33.4 | Affimed raised €25M (US$33.4M) in a Series B round led by BioMedInvest, OrbiMed Advisors LLC and Life Sciences Partners, as well as FirstVentury |
| Argos Therapeutics Inc. |
Durham, N.C. | 4/20 | $5 | Argos raised $5M in a three-year financing arrangement with Silicon Valley Bank and Oxford Finance Corp. |
| Ascenta Therapeutics Inc. |
San Diego | 4/10 | $50 | Ascenta raised $30M in the first tranche of a Series C financing; investors were Perseus LLC, Domain Associates, Sofinnova Ventures, Enterprise Partners, Scale Venture Partners and US Venture Partners |
| aTyr Pharma | San Diego | 4/18 | $10.5 | aTyr closed a Series B round co-led by Alta Partners and Polaris Venture Partners; other investors were Imagene and Cardinal Partners |
| Bionas GmbH | Rostock, Germany | 4/11 | €2.1 ($2.8) |
Bionas closed a $2.8M financing; participants included Genius Venture Capital GmbH and the KfW-Bankengruppe |
| DiObex Inc. | San Francisco | 4/16 | $24 | DiObex closed a $24M Series B financing led by Inventages Venture Capital SA; other investors were Mitsui Ventures, Pac-Link Bioventures, Domain Associates LLC, Pequot Ventures and Sofinnova Ventures |
| Egalet A/S | Copenhagen, Denmark | 4/2 | $19.3 | Egalet raised $19.3M in a Series B round led by Vaekstfonden Life Sciences Ventures; it included existing investors Atlas Venture, Bio Fund, Dansk Kapitalanlaeg, Danske Bank, Index Ventures and QueQuoin Holdings Ltd. |
| Ganymed Pharmaceuticals AG |
Mainz, Germany | 4/18 | €33.7 ($45.7) |
Ganymed closed a $45.7M Series C financing round led by VI Partners; the financing was underwritten by Future Capital, Ingro Finanz, Landesbank Baden-Wurtembert, MIG, Nextech Venture, ONC Partners, Varuma and a consortium of mainly Swiss private investors |
| GenVault Corp. | Carlsbad, Calif. | 4/4 | $18 | GenVault raised $18M in a round with investors QuestMark Partners and Domain Associates |
| Meditrina Pharmaceuticals Inc. |
Ann Arbor, Mich. | 4/4 | $4.4 | Meditrina secured $4.4M in initial funding from the 21st Century Jobs Fund administered by the Michigan Economic Development Corp. and from the Biosciences Research and Commercialization Center at Western Michigan University |
| Metabolex Inc. |
Hayward, Calif. | 4/19 | $32 | Metabolex raised $32M in a Series D round led by MPM BioEquities; other investors were AllianceBernstein, Deerfield Management, T. Rowe Price, Alta Partners, Bay City Capital, Biotech Turnaround Fund, Birchmere Ventures, Johnson & Johnson Development Corp., KBC Funds, Lombard Odier Darier Hentsch, Pictet Funds Biotech, Merlin BioMed Group, Novo Ventures, VantagePoint Venture Partners, Venrock Partners and Versant Ventures |
|
Motif Biosciences Inc. (subsidiary of Amphion Innovations plc) |
New York | 4/5 | $1 | Motif raised $1M in a Series C financing; Amphion invested $400,000 in the round |
| Nautilus Biotech |
Paris | 4/30 | €8.4 ($11.3) |
Nautilus raised $11.3M in a round led by Creabilis Biotech, Ed.de Rothschild Investment Partners, Auriga Partners, Matignon Technologies, Pre-IPO Invest, FCJE, 123 Ventures and Genopole |
| Nitec Pharma AG |
Basel, Switzerland | 4/4** | CHF32 ($26.3) |
Nitec raised $26.3M in a Series B round led by NGN Capital; existing investors Atlas Venture and Global Life Sciences Ventures also participated |
| NuGEN Technologies Inc. |
San Carlos, Calif. | 4/20 | $3 | NuGEN received $3M from Hercules Technology Growth Capital Inc. |
| Protemix Corp. Ltd. |
Auckland, New Zealand | 4/4 | $14.5 | Protemix raised $14.5M in a Series A preferred round co-led by the Novartis Venture Fund and NovaQuest, along with Birnie Capital Ltd. |
|
Radius (formerly Nuvios Inc.) |
Cambridge, Mass. | 4/2 | $29 | Radius raised $29M of a potential $57.5M in a Series C round led by MPM Capital and The Wellcome Trust; they were joined by HealthCare Ventures, Oxford Bioscience Partners, BB Biotech Ventures and Scottish Widows Investment Partnership; the remaining funds will come upon the achievement of certain conditions |
| Sangart Inc. |
San Diego | 4/4 | $50 | Sangart raised $50M in the Series F round led by Leucadia National Corp. |
| Sirion Therapeutics Inc. |
Tampa, Fla. | 4/9 | $45 | Sirion raised $45M in a Series B financing led by Aisling Capital; other investors were Investor Growth Capital, Atlas Venture, Advent International and Bear Stearns Healthcare Value Partners |
| Surface Logix Inc. |
Boston | 4/3 | $20 | Surface Logix raised an additional $20M tranche in a Series D round, bringing the total raised to $52M; it was started in October 2005; Venrock Associates, ARCH Venture Partners, CW Group, HBM BioVentures, Unilever Technology Ventures and others participated |
| Syndax Pharmaceuticals Inc. |
Waltham, Mass. | 4/3 | $40 | Syndax raised $40M in a Series A led by Domain Associates and MPM Capital; it included investments from Avalon Ventures, Forward Ventures and Pappas Ventures |
| | ||||
| Notes: | ||||
| Currency conversions are based on exchange rates at the time of the deal. | ||||
| ** Denotes the date the item ran in BioWorld International. | ||||
| ND = Not disclosed. | ||||
To read more on related topics, click on one of the words below.